
Ad hoc announcement pursuant to Art. 53 LR ZUG, Switzerland — Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion US…
In Fillers, the U.S. FDA approved Restylane Lyft with Lidocaine in November 2025 for augmentation of the chin region to improve the chin profile in patients over the age of 21 with mild-to-moderate c… [+7773 chars]






